Scientists hijack brain's glucose preference to deliver mRNA across blood-brain barrier
Two major breakthroughs this week could transform how we deliver mRNA therapies: one team figured out how to smuggle mRNA past the brain's protective barrier, while another created virus-like delivery vehicles that are dramatically more effective than current lipid nanoparticles.
π§ Scientists hijack brain's glucose preference to deliver mRNA across blood-brain barrier
Researchers created glucose-decorated nanoparticles that exploit the brain's sugar dependency to sneak mRNA past the blood-brain barrierβthe biggest obstacle to treating brain diseases with genetic medicines
Fasting mice for 16 hours upregulated glucose transporters by 4.2-fold, then a glucose spike drove the nanoparticles across the barrier via receptor-mediated transport
The strategy achieved 160-fold higher brain mRNA accumulation compared to untargeted controls, with widespread protein expression visible within 2 hours
Why it matters: The blood-brain barrier blocks 98% of potential brain drugs, making this glucose-hijacking approach a potential game-changer for treating neurological diseases like Alzheimer's, Parkinson's, and brain tumors with mRNA therapies.
Key Findings
π¦ Virus-like particles deliver mRNA 60x more effectively than current vaccine technology
Scientists engineered dual-fusogenic virus-like particles that target dendritic cells and fuse with both cell membranes and internal compartments
The system achieved 28.2% mRNA delivery efficiency to the cytoplasmβabout 60 times greater than standard lipid nanoparticles
At just 50 nanograms of mRNA per mouse (an extremely low dose), the particles triggered strong immune responses against both SARS-CoV-2 and cancer antigens
π― Smart nanoparticles detect tumor stiffness to deliver cancer-fighting mRNA
Engineers created particles with soft membranes that only fuse with soft cancer cells, avoiding healthy tissue with stiffer membranes
The stiffness-gated system boosted mRNA delivery to tumors by 5.2-fold for reporter genes and 4.2-fold for therapeutic p53 tumor suppressor mRNA
Non-target cells rapidly degraded the particles in cellular waste compartments, significantly reducing off-target toxicity compared to conventional delivery systems
π§ Simple DNA modification eliminates toxic RNA byproducts in mRNA manufacturing
Researchers discovered that placing a single nick in template DNA prevents formation of double-stranded RNA contaminants that trigger unwanted immune responses
The "NiLoT" (nicked low dsRNA template) method works by promoting R-loop formation that blocks antisense RNA synthesis during manufacturing
The technique maintains RNA yield while enhancing protein production and reducing immune activation in human cells
π€° Targeted mRNA therapy improves fertility in mice with uterine damage
Scientists developed ligand-conjugated nanoparticles that bind to integrin receptors temporarily overexpressed on the uterine lining during implantation windows
A single intrauterine infusion of GM-CSF mRNA sustained local protein expression for hours while reducing systemic exposure
In mice with endometrial injury, the targeted mRNA treatment improved embryo implantation rates better than recombinant protein therapy
π Longer, segmented mRNA tails boost protein production 6-fold
Researchers designed 15 novel polyA tail variants with heteronucleotide spacers to prevent DNA recombination during bacterial amplification
A segmented tail exceeding 200 nucleotides [A30(CA15)11] increased protein production up to 6-fold compared to standard 90-nucleotide tails
Even frequent spacer insertions maintained functional polyA activity, expanding possible modification strategies for mRNA therapeutics
𧬠Engineered mRNA system prevents heart damage from chemotherapy
Scientists created a cardiac-selective mRNA delivery system using microRNA guides (miR143 and miR122) to suppress expression in off-target tissues including tumors
Weekly intravenous delivery of acid ceramidase mRNA prevented heart dysfunction, fibrosis, and muscle wasting in chronic doxorubicin toxicity models
The treatment protected hearts without compromising the anti-cancer effects of chemotherapy or causing overall toxicity
Implications
These advances collectively address mRNA therapy's biggest challenges: getting past biological barriers, improving delivery efficiency, reducing manufacturing problems, and achieving tissue selectivity. The combination of smarter targeting, better manufacturing, and more effective delivery vehicles could finally unlock mRNA's potential beyond vaccines to treat brain diseases, cancer, and organ damage.
Studies in this issue
Primary sources used for this newsletter.
- Using stabilized micelles targeting glucose transporters to deliver mRNA noninvasively across the blood-brain barriermain storyBioconjugate chemistry2026-01-16PMID 41543443
- Template nicking reduces unwanted opposite-strand RNA production during in vitro transcription by displacing strands through R-loop formationkey findingNucleic acids research2026-01-15PMID 41538313
- Delivering messenger RNA nanoparticles to the uterine lining over time to treat reproductive disorderskey findingNature nanotechnology2026-01-19PMID 41555025
- Adding a PolyA tail improves DNA stability and helps lab-made mRNA produce proteins betterkey findingNucleic acids research2026-01-15PMID 41538312
- A virus-like carrier that fuses twice to deliver mRNA vaccines directly into immune cellskey findingACS nano2026-01-19PMID 41549530
- Stiffness-Controlled Delivery of Messenger RNA into Cells Using Designed Membrane Fusion for Breast Cancer Immunotherapykey findingAdvanced materials (Deerfield Beach, Fla.)2026-01-17PMID 41546399
- A targeted mRNA delivery system to prevent heart damage from chemotherapykey findingAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-01-16PMID 41545029
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.